Pfizer 4Q Revenues: $17.6 billion (-1%)  4Q Loss: $1.6 billion (earnings were $411 million 4Q25)  FY Revenues: $62.6 billion (-2%)  FY Earnings: $7.8 billion (-3%)  Comments: Revenue in the quarter reflects an operational decrease primarily driven by a year-over-year decline in COVID-19 products, partially offset by an increase in revenues for Abrysvo, Oncology biosimilars, Eliquis, the Prevnar family, the Vyndaqel family, and several other products. Excluding ...